Medigus Ltd. (NASDAQ:MDGS) does about 435.47K shares in volume on a normal day but saw 30753972 shares change hands in Friday trading. The company now has a market cap of 11.34M USD. Its current market price is $1.48, marking an increase of 8.03% compared to the previous close of $1.37. The 52 week high reached by this stock is $5.15 whilst the lowest price level in 52 weeks is $0.83. The script in recent trading has seen the stock touch a high of $1.97 and a low of $1.37.
Medigus Ltd. (MDGS) has a 20-day trading average at $1.5270 and the current price is -71.26% off the 52-week high compared with 78.31% distance from its 52-week low. The 50-day simple moving average of the closing price is $1.6139 and its 200-day simple moving average is $1.7799. If we look at the stock’s price movements over the week, volatility stands at 15.25%, which decreases to 7.11% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 45.67 to suggest the stock is neutral.
1 analysts observing the Medigus Ltd. (MDGS) stock have set the 12-month price targets for the company’s shares at between $158.61 and $158.61. The median price target is 99.07% away from the current levels at $158.61.
FactSet Research has provided data showing that 1 brokerages have issued ratings for the stock. 0 analysts have rated it as a sell, while 0 advise that it is a overweight. 1 analysts have rated it as a buy and 0 have advised that investors hold their positions. The consensus recommendation rating is Buy.
The current price level is -3.46%, -8.72%, and -16.93% away from its SMA20, SMA50, and SMA200 respectively, with the MDGS price moving above the 50-day SMA on August 28. Medigus Ltd. (MDGS) stock is up 2.07% over the week and -8.07% over the past month. Its price is -14.94% year-to-date and -27.80% over the past year.
Its 12-month price target is $158.61. Of course, the average price target is just what the average analysts believe a stock will be worth in the next 52 weeks, and is only one metric. There are analysts with lower targets than the average, including one bearish Wall Street research firm advocating investors to wait for the price to pull back to $158.61, given the recent momentum. And then, on the bullish side of things, one analyst is expecting the stock to peak at $158.61.
Outstanding shares total 7.66M with insiders holding 11.57% of the shares and institutional holders owning 37.13% of the company’s common stock. Price to book ratio is 0.91 and price to sales ratio is 41.52.